Awaiting critical Remdesivir safety data from companies: DCGI

Apart from BDR, all have entered into voluntary licensing agreements with Gilead Science, US-based patent holder of this drug. Gilead said the timeline to get Remdesivir to Indian patients will depend on licensees and aprocess it does not control.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/30MUcRl
via IFTTT